What age group is Adagrasib suitable for?

Adagrasib is a selective inhibitor of the KRAS G12C mutation and is mainly used to treat patients with solid tumors such as non-small cell lung cancer (NSCLC) suffering from this mutation. In terms of the user population, the current clinical trial data and drug instructions mainly focus on adult patients, especially middle-aged and elderly people, because KRAS G12C mutations are more common in cancer patients over 50 years old.

The indications for adagrasib are mainly based on clinical research data on adult patients 18 years old and above. In key clinical trials (such as the KRYSTAL-1 study), the average age of enrolled patients is mostly around 60 years old, covering a large number of middle-aged and elderly people. The trial results show that the drug has good efficacy and relatively controllable safety in patients of this age group. Therefore, adagrasib is currently more suitable for use by middle-aged and elderly adults.

For elderly patients (such as70 years old and above), although their metabolic functions are weakened and they have more underlying diseases, adagrasib did not show significantly different pharmacokinetic parameters or increased toxicity trends in the trial. However, in clinical practice, the medication regimen should still be carefully evaluated based on the individual's liver and kidney function status, other medication conditions, and tolerance ability. If necessary, dose reduction should be considered and monitoring should be strengthened.

As forchildren or adolescents under the age of 18, there is currently insufficient clinical data to support its safety and effectiveness in this population, so routine use is not recommended. If relevant research is carried out in the field of children's tumor treatment in the future and data support is obtained, the applicable population may be expanded. However, so far, adagrasib is still only recommended for use in adults, especially patients with advanced solid tumors confirmed by genetic testing to be positive for KRAS G12C mutations.

In summary, the use of adagrasib is mainly aimed at adults, especially middle-aged and elderly patientsKRAS G12C mutation cancer patients. For elderly patients, individualized assessment of medication risks is required. However, for children and adolescents, its use is not yet recommended, and more research evidence is needed to support it.

Reference materials:https://www.drugs.com/